Switch Language

Brand Navigation Banner DE

76 years, Metastatic NSCLC adenocarcinoma

33 years, Papillary thyroid cancer

85 years, MSI-high colorectal cancer

PATIENT CASE

33 years, Papillary thyroid cancer

Alt tag

Overview

Clinical presentation1

• Diagnosed at 27 years

 

Prior treatment1

• 5 prior surgeries

• Radioactive iodine (2 treatments with a cumulative dose of 330 mCi/12.2 GBq; RAI non-avid) 

• Pazopanib and trametinib

 

ETV6–NTRK3 gene fusion detected

Treatment

Treatment with Larotrectinib 100 mg twice daily1

• Confirmed partial response 
   (92.6% reduction in target lesions)

 

Current status1

Larotrectinib treatment is ongoing 
   after 51 cycles

 

Baseline

Alt tag
Alt tag

Cycle 31, Day 26

Alt tag
Alt tag

Larotrectinib is effective in TRK fusion thyroid cancer

Efficacy in TRK fusion thyroid cancer1

• N=28 patients:
   N=21 differentiated / N=7 anaplastic

75% ORR all (95% CI 55-89)

  90% ORR DTC (95% CI 70-99),
  29% ORR anaplastic (95% CI 4-71)
Median OS 27.8 months
  (95% CI 16.7-NE)

 

Safety in TRK fusion thyroid cancer2

• AEs primarily grade 1 and 2

• Treatment-related grade 3 AEs 
  in 2 patients (7%), no grade 4 TRAE

• No permanent discontinuations 
  due to TRAE

 

Maximum change in tumor size (%)2

Alt tag

Based on data cut-off July, 2019; presented at ESMO Virtual Congress 2020. One patient with anaplastic thyroid cancer had clinical disease progression prior to the first tumor response assessment. AE, adverse event; ORR, objective response rate; OS, overall survival; TRAE, treatment-related adverse event

Information professionnelle VITRAKVI®

Picture of the actual patient has been redacted. GBq, gigabecquerel; mCi, millicurie; RAI, radioactive iodine.

References:

  • Waguespack SG, et al. Treatment of advanced TRK fusion thyroid cancer with Larotrectinib. Eur Thyroid J 2019;8(suppl 1):1-127; Abstract OP-01-01. Oral presentation at ETA Annual Meeting on September 7, 2019. Return to content
  • Cabanillas ME, et al. Larotrectinib treatment of advanced TRK fusion thyroid cancer. Ann Oncol 2020;31(suppl 4):S1086, Abstract 1916P. Poster presentation at ESMO Virtual Congress, September 19–21, 2020. Return to content